Impact and Determinants of High-Sensitivity Cardiac Troponin-T Concentration in Patients With COVID-19 Admitted to Critical Care.


Journal

The American journal of cardiology
ISSN: 1879-1913
Titre abrégé: Am J Cardiol
Pays: United States
ID NLM: 0207277

Informations de publication

Date de publication:
15 05 2021
Historique:
received: 29 12 2020
revised: 15 01 2021
accepted: 19 01 2021
pubmed: 23 2 2021
medline: 5 5 2021
entrez: 22 2 2021
Statut: ppublish

Résumé

Cardiac Troponin (hs-TnT) elevation has been reported in unselected patients hospitalized with COVID-19 however the mechanism and relationship with mortality remain unclear. Consecutive patients admitted to a high-volume intensive care unit (ICU) in London with severe COVID-19 pneumonitis were included if hs-TnT concentration at admission was known. Kaplan-Meier survival analysis performed, with cohorts classified a priori by multiples of the upper limit of normal (ULN). 277 patients were admitted during a 7-week period in 2020; 176 were included (90% received invasive ventilation). hs-TnT at admission was 16.5 (9.0 to 49.3) ng/L, 56% had concentrations >ULN. 56 patients (31.8%) died during the index admission. Admission hs-TnT level was lower in survivors (12.0 (8.0-27.8) vs 28.5 (14.0 to 81.0) ng/L, p = 0.001). Univariate predictors of mortality were age, APACHE-II Score and admission hs-TnT (HR 1.73, p = 0.007). By multivariate regression, only age (HR 1.33, CI: 1.16.to 1.51, p < 0.01) and admission hs-TnT (HR 1.94, CI: 1.22 to 3.10, p = 0.006) remained predictive. Survival was significantly lower when admission hs-TnT was >ULN (log-rank p-value<0.001). Peak hs-TnT was higher in those who died but was not predictive of death after adjustment for other factors. In conclusion, in critically ill patients with COVID-19 pneumonitis, the hs-TnT level at admission is a powerful independent predictor of the likelihood of surviving to discharge from ICU. In most cases, hs-TnT elevation does not represent major myocardial injury but acts as a sensitive integrated biomarker of global stress. Whether stratification based on admission Troponin level could be used to guide prognostication and management warrants further evaluation.

Identifiants

pubmed: 33617816
pii: S0002-9149(21)00148-X
doi: 10.1016/j.amjcard.2021.01.037
pmc: PMC7895690
pii:
doi:

Substances chimiques

Biomarkers 0
Troponin T 0

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

129-136

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Interests The authors declare that they have no known competing financial interests or personal relations that could have appeared to influence the work reported in this study.

Auteurs

Ozan M Demir (OM)

NIHR Biomedical Research Centre and British Heart Foundation Centre of Excellence, School of Cardiovascular Medicine and Sciences, King's College London, United Kingdom.

Matthew Ryan (M)

NIHR Biomedical Research Centre and British Heart Foundation Centre of Excellence, School of Cardiovascular Medicine and Sciences, King's College London, United Kingdom.

Chiara Cirillo (C)

School of Imaging Sciences and Biomedical Engineering, King's College London, United Kingdom.

Nishita Desai (N)

Guy's and St Thomas' Hospital NHS Trust, London, United Kingdom.

Ana Pericao (A)

Guy's and St Thomas' Hospital NHS Trust, London, United Kingdom.

Hannah Sinclair (H)

Guy's and St Thomas' Hospital NHS Trust, London, United Kingdom.

Vasileios Stylianidis (V)

Guy's and St Thomas' Hospital NHS Trust, London, United Kingdom.

Kelly Victor (K)

Guy's and St Thomas' Hospital NHS Trust, London, United Kingdom.

Bashir Alaour (B)

NIHR Biomedical Research Centre and British Heart Foundation Centre of Excellence, School of Cardiovascular Medicine and Sciences, King's College London, United Kingdom.

Andrew Jones (A)

Guy's and St Thomas' Hospital NHS Trust, London, United Kingdom.

Antonis N Pavlidis (AN)

Guy's and St Thomas' Hospital NHS Trust, London, United Kingdom.

Andrew Retter (A)

Guy's and St Thomas' Hospital NHS Trust, London, United Kingdom.

Gerald Carr-White (G)

School of Imaging Sciences and Biomedical Engineering, King's College London, United Kingdom; Guy's and St Thomas' Hospital NHS Trust, London, United Kingdom.

Luigi Camporota (L)

Guy's and St Thomas' Hospital NHS Trust, London, United Kingdom.

Nicholas Barrett (N)

Guy's and St Thomas' Hospital NHS Trust, London, United Kingdom.

Michael Marber (M)

NIHR Biomedical Research Centre and British Heart Foundation Centre of Excellence, School of Cardiovascular Medicine and Sciences, King's College London, United Kingdom.

Divaka Perera (D)

NIHR Biomedical Research Centre and British Heart Foundation Centre of Excellence, School of Cardiovascular Medicine and Sciences, King's College London, United Kingdom; Guy's and St Thomas' Hospital NHS Trust, London, United Kingdom. Electronic address: Divaka.Perera@kcl.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH